drugset / Trial / NCT00595829
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
Timeline
- Start
- 2007-12
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XL019 | Unknown | — | Oral |